Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2 :209–218.
White NJ, 2004. Antimalarial drug resistance. J Clin Invest 113 :1084–1092.
White NJ, Olliaro PL, 1996. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12 :399–401.
Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, Thimasarn K, 2001. Drug resistant malaria along the Thai-Myanmar and Thai-Cambodia borders. Southeast Asian J Trop Med Public Health 32 :41–49.
Rojanawatsirivet C, Congpuong K, Vijaykadja S, Thongphua S, Thongsri K, Na Bangchang K, Wilairatana P, Wernsdorfer W, 2004. Declining mefloquine sensitivity of Plasmodium falciparum along the Thai-Myanmar border. Southeast Asian J Trop Med Public Health 35 :560–565.
Nelson A, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sabaithip S, Miller RS, Wongsrichanalai C, Meshnick SR, 2005. PfMDR1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg 72 :586–592.
Gordi T, Lepist EI, 2004. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 147 :99–107.
Taylor WRJ, White NJ, 2004. Antimalarial drug toxicity: a review. Drug Saf 27 :25–61.
Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ, 1999. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 28 :808–815.
Ministry of Public Health, 2004. Manual of Malaria Treatment. Nonthaburi, Thailand: Minstry of Public Health.
Fungladda W, Hornado ER, Thimasarn K, Kitayaporn D, Karbwang J, Kamolratanakul P, Masngammueng R, 1998. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 76 (Suppl 1):59–66.
McGready R, Brockman A, Cho T, Cho D, van Vugt M, Luxemburger C, Chongsuphajaisiddhi T, White NJ, Nosten F, 2000. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum in pregnancy. Trans R Soc Trop Med Hyg 94 :689–693.
Gingras BA, Jensen JB, 1992. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg 47 :378–382.
Ohrt C, Willingmyre GD, Lee P, Knirsch C, Milhous W, 2002. Assessment of azithromycin in combination with other anti-malarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 46 :2518–2524.
World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 :(Suppl 1):S1–S90.
Forney JR, Magill AJ, Wongsrichanalai C, Sirichaisinthop J, Bautista CT, Heppner DG, Miller RS, Ockenhouse CF, Gubanov A, Shafer R, DeWitt CC, Quino-Ascurra HA, Kester KE, Kain KC, Walsh DS, Ballou WR, Gasser RA Jr, 2001. Malaria rapid diagnostic devices: performance of the ParaSight F device determined in a multisite field study. J Clin Microbiol 39 :2884–2890.
Webster HK, Boudreau EF, Pavanand K, Yongvanitchit K, Pang LW, 1985. Antimalarial drug sensitivity testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. Am J Trop Med Hyg 34 :228–235.
Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR, 2003. Resistance to antimalarials in southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 47 :2418–2423.
Bunnag D, Karbwang J, Na-Bangchang K, Thanavibul A, Chittamas S, Harinasuta T, 1996. Quinine-tetracycline for multi-drug resistant falciparum malaria. Southeast Asian J Trop Med Public Health 27 :15–18.
McGready R, Cho T, Samuel , Villegas L, Brockman A, van Vugt M, Looareesuwan S, White NJ, Nosten F, 2001. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans Royal Soc Trop Med Hyg 95 :651–656.
Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, Delmont J, Brouqui P, 2001. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 45 :932–935.
Stauffer W, Fischer PR, 2003. Diagnosis and treatment of malaria in children. Clin Infect Dis 37 :1340–1348.
Andersen AL, Ager A, McGreevy P, Schuster BG, Wesche D, Kuschner R, Ohrt C, Ellis W, Rossan R, Berman J, 1995. Activity of azithromycin as a blood schizonticide against rodent and human malaria in vivo. Am J Trop Med Hyg 52 :159–161.
Yeo AE, Rieckmann KH, 1995. Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int J Parasitol 25 :531–532.
Kuschner RA, Heppner DG, Andersen SL, Wellde BT, Hall T, Schneider I, Ballou WR, Foulds G, Sadoff JC, Schuster B, 1994. Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum. Lancet 343 :1396–1397.
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD, 1998. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis 26 :146–150.
Taylor WRJ, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J, 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 28 :74–81.
Heppner DG, Walsh DS, Uthaimongkol N, Tang DB, Tulyanon S, Permpanich B, Wimonwattrawatee T, Chuanak N, Laoboonchai A, Sookto P, Brewer TG, McDaniel P, Eamsila C, Yongvanitchit K, Uhl K, Kyle DE, Keep LW, Miller RE, Wongsrichanalai C, 2005. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in western Thailand. Am J Trop Med Hyg 73 :842–849.
Na-Bangchang K, Kanda T, Tipawangso P, Thanavibul A, Suprakob K, Ibrahim M, Wattanagoon Y, Karbwang J, 1996. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant malaria. Southeast Asian J Trop Med Public Health 27 :522–525.
DeVries PJ, Le NH, Le TDT, Ho PL, Nguyen VN, Trinh KA, Kager PA, 1999. Short course of azithromycin/artesunate against falciparum malaria: no full protection against recrudescence. Trop Med Int Health 4 :407–408.
Krudsood S, Silachamroon U, Wilairatana P, Singhasivanon P, Phumratanaprapin W, Chalermrut K, Phophak N, Popa C, 2000. A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 31 :801–807.
Krudsood S, Buchachart K, Chalemrut K, Charusabha C, Treeprasertsuk S, Haoharn O, Duangdee C, Looareesuwan S, 2002. A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health 33 :525– 531.
Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, Patel K, Mohapatra MK, Lakhani J, Benner R, Lele C, Patki K, 2005. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 191 :1582–1588.
Shih CM, Wang CC, 1998. Ability of azithromycin in combination with quinine for the elimination of babesial infection in humans. Am J Trop Med Hyg 59 :509–512.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||312||116||0|
Azithromycin, the most potent antimalarial macrolide antibiotic, is synergistic with quinine against Plasmodium falciparum in vitro. We assessed combinations of azithromycin and quinine against uncomplicated P. falciparum malaria at the Armed Forces Research Institute of Medical Sciences–Kwai River Clinical Center along the Thailand-Myanmar border, an area with a high prevalence of multidrug-resistant P. falciparum. Four regimens were assessed in an open-label dose-ranging design involving 61 volunteers. All received oral quinine (Q; 30 mg/kg/day divided every 8 hours for 3 days) with oral azithromycin (Az; 500 mg twice a day for 3 days, 500 mg twice a day for 5 days, or 500 mg three times a day for 3 days). A comparator group received quinine and doxycycline (Dx; 100 mg twice a day for 7 days). Study observation was 28 days per protocol. Sixty volunteers completed the study. Seven days of QDx cured 100% of the volunteers. One failure occurred in the lowest QAz regimen (on day 28) and none occurred in either of the two higher Az regimens. Cinchonism occurred in nearly all subjects. Overall, the azithromycin regimens were well tolerated, and no volunteers discontinued therapy. Three- and five-day azithromycin-quinine combination therapy appears safe, well tolerated, and effective in curing drug-resistant P. falciparum malaria. Further evaluation, especially in pediatric and obstetric populations, is warranted.